Our company has installed and is operating the IQB Gate and Future Laboratory Data® (hereinafter referred to as FLD®) in the main building of the Institute of Quantitative Biosciences at the University of Tokyo. Last year, we set up FLD® in the new main building, and it continues to operate in facilities extensively utilized by …
As outlined in the information dated January 24, 2025, our company is collaborating with the Institute of Medical Science at the University of Tokyo (hereinafter referred to as “the Institute”) to undertake research on the mechanisms of cancer pathogenesis and progression. In conjunction with this effort, we are advancing the development of future technology that …
Our company has initiated an advanced industry-academia collaborative project with the Institute of Medical Science at the University of Tokyo. As we reported in a recent press release, we are engaging in multifaceted cooperation and collaboration on vaccine research and analysis with the Institute of Medical Science at the University of Tokyo. In this initiative, …
We entered into a special agreement with the National University Corporation, the University of Tokyo (hereinafter referred to as “the University of Tokyo”), in 2021. Since the conclusion of this agreement, we have been collaborating with research institutions and laboratories affiliated with the University of Tokyo to advance the development of next-generation cutting-edge technologies. We …
We began the release of the Android application “FLD HbA1c” at the end of September 2025, and since December 17, 2025, we have commenced the release of “FLD SpO2,” which enables estimate of pulse rate and oxygen saturation. As of December 23, 2025, the FLD app series is available in 21 countries worldwide. We are …
Our company, after many years of foundational research, presented the accuracy evaluation of our completely contactless and non-invasive bioinformatic analysis technology for HbA1c estimate at the National Conference of the Japanese Society of Laboratory Medicine on August 29, 2025. In addition, we announced the Android version of our contactless, non-invasive LDL cholesterol estimate app on …
Read more “Regarding the Completion of the Development of the HDL Cholesterol Estimate App for iOS”
Starting from the end of September 2025, we commenced the release of the Android app “FLD HbA1c,” and from December 17, 2025, we began the release of “FLD SpO2,” which allows the estimate of pulse and oxygen saturation. By December 23, 2025, the FLD app series became available in 21 countries worldwide. We are pleased …
We are pleased to announce that the Android app “FLD SpO2” was officially released on December 17, 2025. We are also delighted to inform you that the availability of “FLD SpO2” has expanded to include three additional countries. The newly included countries are as follows: With this expansion, the usage of the FLD app series …
Read more “The number of countries where the FLD series app is available has increased.”
Our company has announced the accuracy evaluation of a completely non-contact, non-invasive biometric information analysis technology for HbA1c estimate at the National Conference of the Japanese Society of Laboratory Medicine, following years of fundamental research, on August 29, 2025. Additionally, we have announced the completion of the development of a non-contact, non-invasive LDL cholesterol estimate …
Read more “Regarding the Completion of Development of the HDL Cholesterol Estimate App for Android”
We are pleased to announce the launch of the Android application ‘FLD HbA1c’, which began at the end of September 2025, and the launch of ‘FLD SpO2’, capable of estimating pulse rate and oxygen saturation, available in 19 countries starting December 17, 2025. We would like to inform you that within approximately two months, the …